MedPath
HSA Approval

PEMAZYRE TABLETS 13.5 MG

SIN17044P

PEMAZYRE TABLETS 13.5 MG

PEMAZYRE TABLETS 13.5 MG

July 9, 2024

SPECIALISED THERAPEUTICS ASIA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSPECIALISED THERAPEUTICS ASIA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

L01EN02

Manufacturer Information

SPECIALISED THERAPEUTICS ASIA PTE. LTD.

Lonza Tampa LLC

Active Ingredients

Pemigatinib

13.50 mg

Pemigatinib

Documents

Package Inserts

Pemazyre Tablet PI.pdf

Approved: July 9, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

PEMAZYRE TABLETS 13.5 MG - HSA Approval | MedPath